Additionally, Patricia English, the company's current Chief Accounting Officer, will serve as interim CFO, while the company conducts an external search for a permanent CFO. Hollar will also join the company's Board of Directors. Hollar will succeed Mike Kaufmann, the company's CEO since January 2018. The company separately announced that its Board of Directors has elected Jason Hollar, the company's current Chief Financial Officer, to serve as its next Chief Executive Officer, effective September 1, 2022. Additionally, the company is targeting Medical segment profit of at least $650 million by fiscal year 2025, based on its Medical Improvement Plan. The company reiterated its long-term targets of low to mid-single digit segment profit growth in the Pharmaceutical segment, mid to high-single digit segment profit growth in the Medical segment, and to average a double-digit combined Non-GAAP EPS growth and dividend yield. We remain committed to the essential role our company plays in healthcare and to delivering value for our customers, employees, and investors."ĭiluted weighted average shares outstanding Jason Hollar, CFO of Cardinal Health, said, "Looking forward, we have confidence in our Medical Improvement Plan and our long-term targets for growth. "In addition, the Pharmaceutical segment grew 5% and we generated strong cash flow, returning $1.6 billion to our shareholders through share repurchases and dividends." "In fiscal year 2022, Medical segment performance was significantly impacted by inflation and supply chain constraints," said Mike Kaufmann, CEO of Cardinal Health. Non-GAAP diluted EPS decreased 9% to $5.06 due to the decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit, net of tax effects. Non-GAAP operating earnings decreased 12% to $2.0 billion, primarily due to net inflationary impacts and global supply chain constraints in the Medical segment. GAAP diluted loss per share was $3.35, primarily due to these impairments, net of tax effects. GAAP operating loss was $596 million due to non-cash, pre-tax goodwill impairment charges of $2.1 billion in the Medical segment. Non-GAAP operating earnings increased 41% to $450 million, primarily due to the increase in Pharmaceutical segment profit, and non-GAAP diluted EPS increased 36% to $1.05 in the quarter.įiscal year 2022 revenues were $181.4 billion, a 12% increase from fiscal year 2021. GAAP diluted earnings per share (EPS) were $0.50, primarily due to this impairment, net of tax effects. GAAP operating earnings were $36 million, primarily due to a non-cash, pre-tax goodwill impairment charge of $303 million in the Medical segment. 11, 2022 /PRNewswire/ - Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2022 revenues of $47.1 billion, an increase of 11% from the fourth quarter of last year. Company introduces Medical Improvement Plan, targeting Medical segment profit of at least $650 million by fiscal year 2025ĭUBLIN, Ohio, Aug.Company provides fiscal year 2023 guidance and reiterates long-term targets.Generated operating cash flow of $3.1 billion in fiscal year 2022.Non-GAAP operating earnings increased 41% to $450 million in the fourth quarter non-GAAP diluted EPS increased 36% to $1.05 in the fourth quarter.GAAP 1 operating earnings were $36 million in the fourth quarter GAAP diluted EPS were $0.50 in the fourth quarter.Revenue increased 11% to $47.1 billion in the fourth quarter.Adaptive web solutions supplier Ciena Corporation (NYSE: CIEN) banal has mislaid (-43%) successful the 2022 carnivore marketplace falling for 11 consecutive weeks. The optical fibre shaper is instrumental successful the deployment of 5G infrastructure and maturation successful wireless and accelerated cloud adoption astatine the edge of the network. The Company lowered its fiscal full-year 2022 gross maturation percent to mid-single digits from its 11% to 13% erstwhile outlook. The shortfall comes from the industry-wide supply concatenation constraints against robust merchandise request causing increasing backlog. Ciena’s book-to-bill ratio grew good implicit 1.5X from $2.2 cardinal astatine the extremity of 2021 to implicit $4 cardinal by the extremity of Q2 2022. Many of the low-value commoditized parts indispensable to merchandise of IC and SMIC are superior sourced retired of China, which was impacted by the COVID lockdowns. The important request for Ciena products is further adding to the supply chain challenges arsenic they get worse. The recovery successful the availability of proviso is the astir impactful constituent of show and gross growth. Prudent investors seeking vulnerability successful broadband web infrastructure solutions tin ticker for opportunistic pullbacks successful shares of Ciena.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |